Ad
related to: pfizer 2023 earnings report transcript pdf
Search results
Results From The WOW.Com Content Network
Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street consensus estimates of $62.9 billion, and earnings per share of $3.12 ...
PFE earnings call for the period ending December 31, 2024. ... Our assumptions for 2025 are on par with these 2023 and 2024 patterns. And with the multi-year contracts we have secured in ...
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.
In September 2019, Pfizer initiated a study with the CDC Foundation to investigate the tracking of healthcare-associated infections, scheduled to run through to June 2023. [97] In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its cryptococcal disease screening and treatment research in nine African countries ...
For premium support please call: 800-290-4726 more ways to reach us
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The company completed an initial public offering in March 2001, and prior to its acquisition by Pfizer, it was traded on the Nasdaq Stock Market under the symbol SGEN, and was a component of the Nasdaq-100. As of December 2016, the company has more than 900 employees throughout the United States.
For premium support please call: 800-290-4726 more ways to reach us